Survey for Patients with Relapsed/Refractory DLBCL Lymphoma

Patients or Caregivers of Patients with Relapsed/Refractory DLBCL Lymphoma: We Need Your Help! Lymphoma Canada is preparing a submission for the pan-Canadian Oncology Drug Review (pCODR) for an upcoming drug review on: “Polatuzumab Vedotin (POLIVY) + Bendamustine + Rituximab for relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL)”. The survey will be open until midnight Pacific Time on Wednesday, October 5, and should only take between 15-20 minutes of your time.

If you have DLBCL or are a caregiver of someone with DLBCL that has received this combination treatment, you can help by completing our survey.

The survey provides us with the patient and caregiver input required for the submissions. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.

You do not need to live in Canada to complete this survey.

Find out more information about the survey and Lymphoma Canada by here: https://www.lymphoma.ca/survey-for-patients-with-relapsed-refractory-dlbcl-lymphoma/

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.